Adulteration of opioids with fentanyl and nitazenes has, in part, been responsible for the huge increase in drug related deaths...
View Article
Adulteration of opioids with fentanyl and nitazenes has, in part, been responsible for the huge increase in drug related deaths...
View Article
Sometimes things need shaking up. When I read Robert Bakker’s book the ‘The Dinosaur Heresies’ I was hooked, although my...
View Article
PROTACs, formally known as heterobifunctional degraders, remain an exciting modality for tackling disease-linked proteins long considered “undruggable.” By inducing the...
View Article
The human brain, a marvel of complexity and sophistication, is the epicentre of our consciousness, cognition, and overall well-being. It...
View Article
Amyotrophic lateral sclerosis (ALS) is a fatal late-onset neurodegenerative disorder which affects motor neurons in the brain and spinal cord....
View Article
Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.
We were pleased to host the final ELRIG networking event of 2021 last month at Alderley Park. Synthetic chemistry has...
View Article
Candidate profiling, or late lead optimisation, is the final stage of de-risking and optimising drug candidates with the best chance...
View Article
This month sees the official opening of our new Form and Formulation department. But why are we bringing formulation scientists...
View Article
Drug discovery programmes can be made or broken by the approaches organisations take in the early stages. As project viability...
View Article